FDA approves Novartis high blood pressure drug Tekturna

The FDA gave Novartis AG clearance to market its Tekturna drug to treat high blood pressure, breathing new life into a product the firm had almost given up on seven years ago. Developed with Speedel Holding AG, the drug at one time was considered too expensive to make but now emerges as the first new type of drug in more than a decade for treating high blood pressure.

View Full Article in:

Bloomberg Businessweek · Wall Street Journal (tiered subscription model), The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior Director, Biostatistics
Edwards Lifesciences
Irvine, CA
Diagnostic Technician
Marlborough, MA
Test Technician
Marlborough, MA
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC
Senior Paralegal - Research & Development, and Medical
Boehringer Ingelheim
Ridgefield, CT